Topics
Glioblastoma | Diagnosis | Magnetic resonance imaging | Differentiation
Home > Publications > Topics > Glioblastoma > Diagnosis > Magnetic resonance imaging > Differentiation
Predictors for the Differentiation
Chuthip
P, Sitthinamsuwan B, Witthiwej T, Tansirisithikul C, Khumpalikit
I, Nunta-Aree S.
Predictors
for the Differentiation between Glioblastoma, Primary Central
Nervous System Lymphoma, and Metastasis in Patients with a
Solitary Enhancing Intracranial Mass.
Asian
J Neurosurg.
2024 Jun 6;19(2):186-201. doi:
10.1055/s-0044-1787051. PMID:
38974428. Observational study. ˍ
Dynamic contrast-enhanced MRI
Zhang Y, Luo X, Zhu Y, Zhang Q, Liu B.
Differentiation
between primary central nervous system lymphomas and gliomas
according to pharmacokinetic parameters derived from dynamic
contrast-enhanced magnetic resonance imaging.
Heliyon.
2024 Jun 6;10(12):e32619. doi:
10.1016/j.heliyon.2024.e32619. PMID:
38952379.
Observational study. ˍ
Apparent Diffusion Coefficient
Würtemberger
U, Diebold M, Rau A, Akgün V, Becker L, Beck J, Reinacher PC,
Taschner CA, Reisert M, Fehrenbacher L, Erny D, Scherer F,
Hohenhaus M, Urbach H, Demerath T.
Advanced
diffusion imaging reveals microstructural characteristics of
primary CNS lymphoma, allowing differentiation from glioblastoma.
Neurooncol
Adv.
2024 Jun 8;6(1):vdae093. doi:
10.1093/noajnl/vdae093. PMID:
38946879. Observational study. ˍ
Apparent Diffusion Coefficient
Khalaj K, Jacobs MA, Zhu JJ, Esquenazi Y, Hsu S, Tandon N,
Akhbardeh A, Zhang X, Riascos R, Kamali A.
The
Use of Apparent Diffusion Coefficient Values for Differentiating
Bevacizumab-Related Cytotoxicity from Tumor Recurrence and
Radiation Necrosis in Glioblastoma.
Cancers
(Basel). 2024 Jul 2;16(13):2440. doi:
10.3390/cancers16132440. PMID:
39001500.
Observational study. ˍ
van
Dorth D, Croese RJI, Jiang FY, Schmitz-Abecassis B, Taphoorn MJB,
Smits M, Dirven L, van Osch MJP, de Bresser J, Koekkoek JAF.
Perfusion MRI-based differentiation
between early tumor progression and pseudoprogression in
glioblastoma and its use in clinical practice.
Neurooncol
Pract. 2024 Oct 15;12(2):281-290. doi:
10.1093/nop/npae099. PMID:
40110054. Observational study. ˍ
68Ga-Pentixafor PET in Combination With MRI
Chen Z, Liu H, Yang A, Liao J, Wu Z, Chen J, Miao W.
68Ga-Pentixafor PET in Combination
With MRI Improves the Differential Diagnosis of Glioblastoma and
Primary Central Nervous System Lymphoma.
Clin
Nucl Med. 2025 Jan 6. doi:
10.1097/RLU.0000000000005657. PMID:
39761437. Observational study˰
ˍ
DSC-MR perfusion images
Kuroda H, Okita Y, Arisawa A, Utsugi R, Murakami K, Hirayama R,
Kijima N, Arita H, Kinoshita M, Fujimoto Y, Nakamura H, Kagawa N,
Tomiyama N, Kishima H.
Cerebral blood
flow and histological analysis for the accurate differentiation of
infiltrating tumor and vasogenic edema in glioblastoma.
PLoS
One. 2025 Jan 10;20(1):e0316168. doi:
10.1371/journal.pone.0316168. PMID:
39792964. Observational study. ˍ
Lv XQ, Shen WR, Guo Z, Xie XD.
Diagnostic
value and efficacy of multimodal magnetic resonance imaging in
differentiating radiation necrosis from tumor recurrence in
glioblastomas.
Acta
Radiol. 2025 Feb 4:2841851241310392. doi:
10.1177/02841851241310392. PMID:
39905844. Observational study˰
ˍ